2 weeks Ago By ABMN Staff
Summit Investment Advisors Inc. boosted its holdings in shares of Avidity Biosciences, Inc. ( NASDAQ:RNA – Free Report ) by 6.
1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,611 shares of the biotechnology company’s stock after purchasing an additional 666 shares during the quarter. Summit Investment Advisors Inc.
’s holdings in Avidity Biosciences were worth $338,000 at the end of the most recent reporting period. Other institutional investors also recently bought and sold shares of the company. Van ECK Associates Corp purchased a new stake in shares of Avidity Biosciences during the fourth quarter worth about $38,000.
Headlands Technologies LLC purchased a new stake in Avidity Biosciences during the 4th quarter worth approximately $60,000. KBC Group NV increased its stake in Avidity Biosciences by 99.0% during the 4th quarter.
KBC Group NV now owns 4,474 shares of the biotechnology company’s stock worth $130,000 after buying an additional 2,226 shares in the last quarter. US Bancorp DE raised its holdings in shares of Avidity Biosciences by 25.2% during the fourth quarter.
US Bancorp DE now owns 6,568 shares of the biotechnology company’s stock valued at $191,000 after acquiring an additional 1,324 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in shares of Avidity Biosciences in the fourth quarter valued at approximately $210,000. Analysts Set New Price Targets RNA has been the topic of several recent research reports.
Royal Bank of Canada reaffirmed an “outperform” rating and set a $67.00 target price on shares of Avidity Biosciences in a research note on Tuesday, January 21st. Bank of America lowered their price target on shares of Avidity Biosciences from $51.
00 to $48.00 and set a “buy” rating on the stock in a research report on Monday, March 10th. Barclays decreased their target price on shares of Avidity Biosciences from $63.
00 to $57.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Citigroup initiated coverage on Avidity Biosciences in a research report on Thursday, March 13th.
They issued a “buy” rating and a $70.00 price target for the company. Finally, BMO Capital Markets initiated coverage on Avidity Biosciences in a research report on Wednesday, March 12th.
They set an “outperform” rating and a $72.00 price objective on the stock. Thirteen investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Avidity Biosciences has a consensus rating of “Buy” and an average target price of $66.
69. Avidity Biosciences Trading Up 3.5 % Shares of RNA stock opened at $26.
66 on Monday. The company has a market capitalization of $3.20 billion, a P/E ratio of -9.
26 and a beta of 1.01. The business’s 50 day moving average is $29.
50 and its two-hundred day moving average is $35.05. Avidity Biosciences, Inc.
has a twelve month low of $21.51 and a twelve month high of $56.00.
Avidity Biosciences ( NASDAQ:RNA – Get Free Report ) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.
76) by ($0.04). Avidity Biosciences had a negative net margin of 2,772.
45% and a negative return on equity of 27.66%. The firm had revenue of $2.
97 million during the quarter, compared to analysts’ expectations of $1.74 million. As a group, equities analysts predict that Avidity Biosciences, Inc.
will post -2.89 earnings per share for the current fiscal year. Insider Buying and Selling In related news, CFO Michael F.
Maclean sold 3,287 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $28.59, for a total value of $93,975.
33. Following the completion of the sale, the chief financial officer now owns 104,655 shares in the company, valued at $2,992,086.45.
This trade represents a 3.05 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link .
Also, insider Kathleen P. Gallagher sold 5,875 shares of the business’s stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $27.
83, for a total transaction of $163,501.25. Following the sale, the insider now directly owns 50,554 shares in the company, valued at approximately $1,406,917.
82. This represents a 10.41 % decrease in their position.
The disclosure for this sale can be found here . Insiders sold 79,318 shares of company stock valued at $2,405,390 over the last ninety days. Corporate insiders own 3.
68% of the company’s stock. About Avidity Biosciences ( Free Report ) Avidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics.
The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Read More Want to see what other hedge funds are holding RNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avidity Biosciences, Inc.
( NASDAQ:RNA – Free Report ). Receive News & Ratings for Avidity Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avidity Biosciences and related companies with MarketBeat.com's FREE daily email newsletter .
.
